Please login to the form below

Not currently logged in
Email:
Password:

clinical benefit

This page shows the latest clinical benefit news and features for those working in and with pharma, biotech and healthcare.

Vertex rises on data for cystic fibrosis triple therapy

Vertex rises on data for cystic fibrosis triple therapy

Vertex's Reshma Kewalramani. “These data mark a major milestone in our efforts to develop new CF medicines as they underscore the important clinical benefit that a triple combination regimen may

Latest news

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    Taken together, while checkpoint inhibitors are now the standard of care in frontline RCC, PD-L1-positive patients tend to derive the most benefit,” notes Hsieh. ... In our view, combination with TKI could expand the clinical benefit of checkpoint

  • Alnylam seeks fast-track filing with biomarker data Alnylam seeks fast-track filing with biomarker data

    Aminolevulinic Acid (ALA), a key biomarker likely to predict clinical benefit. ... FDA. to discuss the results and the overall benefit-risk profile for a potential NDA submission at or around year-end in support of an accelerated approval.”.

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    benefit in the “curative-intent, stage III NSCLC setting”, and is the first and only immunotherapy to be approved for these patients. ... The significant survival benefit observed using the PACIFIC regimen provides confidence and clear rationale for

  • ICER says Alnylam’s Onpattro should cost 90%-95% less ICER says Alnylam’s Onpattro should cost 90%-95% less

    its price would have to be reduced 90%-95% to come into line with the benefit to patients. ... However, ICER goes on to say that there “may be uncertainties related to the translation of neurologic outcomes to longer-term clinical benefit, the

  • Biogen and Eisai claim mid-stage win for Alzheimer’s drug Biogen and Eisai claim mid-stage win for Alzheimer’s drug

    They estimate– based on Eisai’s earlier communications on the drug and trial design – that the clinical benefit could be around 20-25% and “certainly very clinically meaningful” if so.

More from news
Approximately 1 fully matching, plus 139 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The scheme. The PRIME scheme is for medicines that have real promise, defined by the EMA as medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients ... Companies who want to benefit from the scheme have to

  • Can new data aggregators shift the balance of power away from pharma? Can new data aggregators shift the balance of power away from pharma?

    This could have far-reaching consequences for some players in the pharmaceutical industry who may find their product pricing to be untenable when the cost/clinical benefit calculus becomes totally transparent.

  • Patient recruitment and engagement standards Patient recruitment and engagement standards

    And the reality: 50% of clinical research sites don’t recruit a single patient. ... A number of studies have revealed that awareness changes patients’ perceptions about clinical trials, enrolment and the risk/benefit ratio of getting involved.

  • Taking a lean and careful approach Taking a lean and careful approach

    Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’. ... Clinical trials. The company is moving cautiously and set its clinical trials in Israel, Italy, Turkey and Greece.

  • Strengthening market access deliverables by harnessing the patient journey Strengthening market access deliverables by harnessing the patient journey

    Topics such as the clinical value of new products, or what impact the product has on outcomes are relevant to multiple stakeholders. ... management, clinical benefit and economic/humanistic benefit.

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... Not only will we benefit from her clinical capabilities in our ongoing pivotal study of

  • ICON's CEO named chair of ACRO ICON's CEO named chair of ACRO

    Trade body for clinical research organisation elects Ciaran Murray. The global trade body for clinical research organisations has elected ICON's CEO Ciaran Murray as chairman. ... I look forward to continuing the work that ACRO has done in promoting our

  • Industry veteran Louis Nisbet joins Sygnature board Industry veteran Louis Nisbet joins Sygnature board

    The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Irritable Bowel Syndrome (IBS) Patient Insights

    Irritable bowel syndrome in adults: diagnosis and management. NICE Clinical Guideline 61; 2017. ... International survey of patients with IBS: Symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J

  • What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

    Balancing doctors’ demands for drugs that demonstrate strong clinical benefit and patient safety against medicines management teams’ focus on cost savings will be critical in CEP areas. ... In such areas, bringing together multi-disciplinary networks

  • How will the NHS’s new medicines savings drive affect pharma?

    Engagement tactics must balance clinicians’ demand for products that show strong clinical benefit and patient safety against medicines management teams’ focus on the cost savings that can be generated by specific ... full benefit of expensive drugs,

  • Why and how doctors should be involved in startups

    provide useful clinical insight that can benefit a startup.

  • Immunotherapy in oncology

    These three states align with the clinical observations of response, stable disease and progression of disease. ... However, the group recognised that delayed responses and prolonged stable disease were having a significant survival benefit, underscoring

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics